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Introduction {#sec1}
============

Studying embryonic stem cell (ESC) differentiation *in vitro* has contributed to understanding early developmental processes while identifying methods to direct differentiation of specific cell types potentially useful to treat a variety of pathophysiologic conditions ([@bib28]). Despite remarkable progress made over two decades, it is not yet feasible to produce hematopoietic stem and progenitor cells (HSPCs) from ESCs that engraft and persist in recipients ([@bib10], [@bib49]). In vertebrates, hematopoiesis occurs in successive waves, producing diverse progenitors with specific potentials ([@bib13], [@bib14]). The first wave is initiated in the yolk sac (YS) blood islands and gives rise to a transient population of primitive red blood cells, diploid megakaryocytes, and primitive macrophages ([@bib4], [@bib46], [@bib56]). A second wave initiating in the YS gives rise to definitive erythroid and myeloid progenitors (EMPs) ([@bib38], [@bib39], [@bib46]). A third wave occurs at embryonic (E) day 10.5 in the major arteries: the dorsal aorta, vitelline artery, and umbilical artery of the aorta-gonad-mesonephros (AGM) region ([@bib14]); this is the first site at which transplantable hematopoietic stem cells (HSCs) are produced. These HSCs and the earlier multipotent progenitors are thought to arise from specialized endothelium (hemogenic endothelium \[HE\]) through an endothelial to hematopoietic transition (EHT) ([@bib3], [@bib5], [@bib15], [@bib18], [@bib34]). *In vitro* differentiation of ESCs from embryoid bodies (EBs) generally recapitulates YS hematopoiesis, and efforts have been made to direct differentiation to produce transplantable HSCs by manipulating intrinsic or extrinsic signals ([@bib10]). Although not all types of progenitor cells can be produced from ESCs *in vitro*, the fact that developmental processes including EHT can be manipulated pharmacologically and genetically makes this system a valuable model to study how hematopoietic commitment occurs and can be influenced ([@bib34]).

*Mll1 (Kmt2a)* loss-of-function murine models implicated this gene as a major regulator of HSPC development and homeostasis including in EBs and embryos ([@bib16], [@bib25], [@bib41], [@bib60]). Our prior findings that MLL1 regulates an HSC-specific target gene repertoire led us to wonder whether increasing MLL1 levels could have an impact on hematopoietic development during the early waves of hematopoiesis. This question, however, has been difficult to address due to the absence of appropriate model systems.

The human *MLL1/KMT2A* gene is a frequent target of chromosomal translocations that cause acute leukemias ([@bib30]). Most translocations produce fusions that exhibit ectopic transactivation capacity. However, partial tandem duplications within the MLL1 gene (MLL-PTD) and occasional cases of *MLL1* amplification have been reported in myelodysplastic syndrome and acute myeloid leukemia (AML), often concomitant with upregulation of MLL1 target genes such as *HOXA7*, *HOXA9*, and *MEIS1* ([@bib11], [@bib47], [@bib54]). Attempts to determine the impact of these non-fusion events or to test the latent oncogenic potential of wild-type (WT) MLL1 protein have been hampered by the challenges of expressing the large *MLL1* cDNA and the fact that MLL1 overexpression arrests cell growth ([@bib24], [@bib36]). Thus, having a model that enables increasing MLL1 levels would be of great significance for multiple mechanistic avenues of investigation. In the current study, we developed a system in which WT MLL1 can be induced within physiologically tolerated ranges. This system revealed that increasing MLL1 protein level only by ∼2-fold enhanced hematopoietic potential. These data also highlight the role of Rac/Rho/integrin signaling during the EHT.

Results {#sec2}
=======

Generation and Validation of WT hMLL1-Inducible ESCs {#sec2.1}
----------------------------------------------------

To achieve consistent and reversible induction of MLL1 *in vitro* and *in vivo*, we generated a doxycycline-inducible MLL1 human (hMLL1i) transgene by integrating a modified cDNA into the murine *Col1a1* locus ([@bib2]) ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Human and mouse MLL1 proteins are 93% similar, and human fusion oncoproteins function in murine cells. Maximal induction of hMLL1 occurred at addition of 2 µg/mL doxycycline, which corresponded to an approximately 2-fold increase in total MLL1 protein ([Figures 1](#fig1){ref-type="fig"}A, 1B, and [S1](#mmc1){ref-type="supplementary-material"}C--S1E). To determine whether H3K4 methylation levels were altered by this increase, we performed western blots on extracted histones ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Consistent with prior results indicating that MLL1 is not a dominant H3K4 methyltransferase ([@bib9], [@bib43]), we found that H3K4me1/2/3 levels were not altered, despite significant changes in gene expression. Co-immunoprecipitation of Menin and Wdr5 demonstrated that induced MLL1 is functional and associates with known complex components ([Figures S1](#mmc1){ref-type="supplementary-material"}G--S1I). Thus, we have developed a system in which physiologically tolerated induction of WT MLL1 can be achieved.Figure 1Induction of Physiologic Levels of WT hMLL1 Does Not Perturb Normal EB Differentiation(A) Quantitative RT-PCR showing total murine + human transcript. WT (KH2) or hMLL1-inducible ESCs were harvested 48 h after doxycycline (Dox) treatment. Phosphate buffered saline (PBS) is the solvent control. Bar graph represents average expression (relative to *Gapdh*) of total *Mll1/MLL1* transcript from three independent experiments ± SEM.(B) Western blot showing induced MLL1 protein. Nuclear protein was extracted from hMLL1-inducible ESCs ± Dox. Nucleolin represents the loading control. The dash shows the MLL1 C terminal peptide (p180); the asterisk marks the degradation product. Quantification reflects western blots from three independent experiments.(C) Images showing morphology of EBs from day 2 to day 6 at 40× magnification. Scale bar for inset, 22.6 mm. Scale bar for bigger picture, 48.9 mm.(D) EB accumulation in different induction schemes. One representative from three independent experiments is shown. Data represent average cell numbers ± SEM, n = quadruplicate cultures. Experiments were performed with hMLL1-inducible ESCs. Dox 0--6 = doxycycline added to differentiation medium from day 0 to day 6; Dox 2-4, doxycycline added to differentiation medium from day 2 to day 4; Dox 4-6 = doxycycline added to differentiation medium from day 4 to day 6.(E--G) Representative gene expression of (E) mesoderm (*Brachyury* and *Flk1*), (F) ectoderm (*Sox1* and *Pax6*), and (G) endoderm (*Sox17* and *Gata6*) during EB differentiation. Experiments were performed with hMLL1-inducible ESCs. PBS was the solvent control and Dox was added to differentiation medium from day 0 to 6. Data represent average expression (relative to *Gapdh*) ± SEM, n = 3 independent experiments.

hMLL1 Induction Does Not Grossly Alter ESC Differentiation {#sec2.2}
----------------------------------------------------------

To first determine whether increasing MLL1 protein influenced germ layer specification and differentiation, several regimens of induction were tested ([Figure S1](#mmc1){ref-type="supplementary-material"}J). EBs generated from differentiated ESCs ± hMLL1 induction throughout the time course exhibited similar morphology and cell accumulation during differentiation ([Figures 1](#fig1){ref-type="fig"}C and 1D). This was true whether hMLL1 induction was performed throughout differentiation or during brief phases of differentiation ([Figure 1](#fig1){ref-type="fig"}D). Genes characteristic of each of the three germ layers were expressed normally in all regimens ([Figures 1](#fig1){ref-type="fig"}E--1G). Thus, maximal hMLL1 induction does not grossly alter overall EB differentiation, cell survival, or proliferation.

Induction of hMLL1 Does Not Significantly Alter Mesoderm Differentiation {#sec2.3}
------------------------------------------------------------------------

The production of hematopoietic cells in EBs occurs through developmental steps paralleling hematopoiesis in the YS of the embryo ([@bib49]). Flk-1 expression encompasses mesodermal cells committed to hematopoietic, endothelial, cardiogenic, and muscle fates ([@bib27], [@bib37], [@bib51]). In our system, Flk-1^+^ cells peak at day 4 of EB differentiation, and this is not altered by hMLL1 induction ([Figure 2](#fig2){ref-type="fig"}A). Flk-1^+^ cells encompass both Pdgfrα^+^ and Pdgfrα^neg^; Flk1^+^/Pdgfrα^+^ cells are cardiogenic, whereas Flk-1^+^/Pdgfrα^neg^ cells contain precursors of endothelial and hematopoietic lineages ([@bib26]). Flk-1^+^/Pdgfrα^neg^ cells give rise to a small population of HE cells that are Cd41^low^/VE-cadherin^+^/Tie-2^+^, which in turn differentiate into Cd41^hi^/Cd45^+^ cells that include hematopoietic progenitor cells ([@bib8], [@bib15], [@bib29], [@bib34], [@bib48]). To test the impact of hMLL1 induction on this developmental progression, we induced hMLL1 during days 2--4 or days 4--7 and determined population frequencies by flow cytometry. hMLL1 induction did not alter Flk-1^+^/Pdgfrα^neg^ cell generation ([Figure 2](#fig2){ref-type="fig"}B). HE cells (c-Kit^+^/Tie-2^+^) were produced in EBs with similar kinetics and in similar proportions except for a small reduction at day 7 in hMLL1-induced cultures ([Figures 2](#fig2){ref-type="fig"}C, [S2](#mmc1){ref-type="supplementary-material"}A, and S2B). Acquisition of hematopoietic markers (Cd41^hi^/Cd45^+^) ([@bib21]) proceeded similarly regardless of hMLL1 induction ([Figure 2](#fig2){ref-type="fig"}D). These data show that overall specification of hemogenic endothelial precursors, as defined immunophenotypically, occurs independent of MLL1 levels.Figure 2Acquisition of Endothelial and Hematopoietic Markers Occurs Normally upon hMLL1 Induction(A) Flk-1 surface expression during differentiation of EBs. One representative of three independent experiments is shown as average live-gated, Flk-1^+^ cells ± SEM of quadruplicate cultures. hMLL1-inducible EBs were treated with vehicle (PBS) or 2 μg/mL doxycycline for indicated days.(B) Generation of hemangioblast-enriched cells shown by flow cytometry. hMLL1i EBs were treated with solvent (PBS) or doxycycline from day 2 to 4. Quadrant gating is based on single stained controls and the hemangioblast-enriched Flk-1^+^/Pdgfrα^neg^ population is indicated in red and quantified in the bar graphs (right). Data are representative of two independent experiments and are shown as the average ± SEM of triplicate cultures.(C and D) (C) Hemogenic endothelium c-Kit^+^/Tie-2^+^ and (D) hematopoietic Cd41^+^/Cd45^+^ were determined and quantified in the bar graphs. hMLL1i EBs were treated with solvent (PBS) or doxycycline from day 4 to 7. Data are representative of three independent experiments and are shown as averages ± SEM of triplicate cultures.

Induction of hMLL1 Selectively Affects c-Kit^+^/Cd41^+^ Hematopoietic Progenitor Function {#sec2.4}
-----------------------------------------------------------------------------------------

To determine whether the emergence of hematopoietic potential was influenced by hMLL1 induction, we determined c-Kit^+^/Cd41^+^ cell frequencies, which represent the first population enriched in multilineage hematopoietic colony forming units (CFU) in EBs ([@bib40]). None of the induction regimens altered the peak frequency or kinetics of c-Kit^+^/Cd41^+^ cell differentiation ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). However, c-Kit^+^/Cd41^+^ cells sorted from hMLL1-induced EBs consistently produced 2-fold more CFU compared with controls ([Figure 3](#fig3){ref-type="fig"}B), which reflected a general increase in all colony types ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). This observation was consistent across two additional, independently targeted hMLL1-inducible clones ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Cells harvested at day 7 of the CFU assay exhibited similar surface phenotypes and morphologies ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}E). The analogous embryo YS-derived EMPs lack B cell potential and are largely Cd16/32^+^ ([@bib33], [@bib39]), which are also features of our EB-derived EMP-like population ([Figure 3](#fig3){ref-type="fig"}C and W.Y., unpublished data). Collectively, these data demonstrate that increasing MLL1 does not influence the production of EMP-like progenitors but selectively increases the hematopoietic potential of the population on a per cell basis.Figure 3hMLL1 Induction Selectively Affects c-Kit+/Cd41 + Hematopoietic Progenitor Function(A) Flow cytometry showing the development of c-Kit^+^/Cd41^+^ cells. Quantification of representative triplicate cultures is shown in the right panel as the average ± SEM.(B) CFU assays with 1,000 sorted c-Kit^+^/Cd41^+^ cells and colonies scored 7 days later. The bar graph shows data pooled from five independent experiments and presented as averages of triplicate cultures ± SEM. GEMM, granulocyte-erythrocyte-monocyte-megakaryocyte; GM, granulocyte-macrophage; E, erythroid.(C) Flow cytometry showing similar phenotype of expanded hematopoietic colonies grown on methylcellulose after 7 days.(D) Cell-cycle status of sorted c-Kit^+^/Cd41^+^ cells as determined by BrdU and 7-aminoactinomycin D (7-AAD) staining, quantification is shown in the right panel. Data show one representative experiment of two, bars indicate the average ± SEM of triplicate cultures.(E) Quantification of 7-AAD low (Sub-2N) cells in the above analyses. Data show one representative experiment of two. Error bar shows the average ± SEM of triplicate cultures.(F) Serial replating of sorted c-Kit^+^/Cd41^+^ progenitors. First round plating was initiated with 1,000 cells. After 7 days, colonies were scored, harvested, and replated using 5,000 cells per dish. Data are normalized to 1,000 input cells. The bar graph shows data pooled from four independent experiments representing triplicate cultures ± SEM.(G) Flow cytometry showing E9.5 YS c-Kit^+^/Cd41^+^ EMPs (top) and quantification (lower left). CFU assays were performed with dissociated E9.5 YS cells and colonies were scored 7 days later. Control embryo genotype = rtTA/+ or hMLL1/+, n = 6; hMLL1-induced embryo genotype = hMLL1/+; rtTA/+, n = 5.(H) Image and quantification of hematopoietic clusters in E10.5 embryo (34 somite pairs). Left, confocal images show c-Kit (blue), Runx1 (green), and Cd31 (red) expression in the mouse dorsal aorta and vitelline artery region. Right, quantification of hematopoietic cluster (c-Kit^+^/Cd31^+^) cells per millimeter of the dorsal aorta. Clusters within five somites centered on the vitelline artery (two somites above, two somites below, and the somite where the vitelline artery connects to the dorsal aorta) were counted. Data represent the average ± SEM, n = 4--8 animals.

To determine how hMLL1 induction increases hematopoietic potential, we first considered whether hMLL1 induction affected survival or proliferation of the newly generated EMP-like cells. Sorted day 6 c-Kit^+^/Cd41^+^ cells were briefly incubated with 5-bromo-2-deoxyuridine (BrdU) in liquid culture to quantify proliferation in control versus hMLL1-induced populations. No differences were observed in BrdU incorporation, cell-cycle phase distribution ([Figure 3](#fig3){ref-type="fig"}D), or cells exhibiting sub-2N DNA content ([Figure 3](#fig3){ref-type="fig"}E). To investigate whether hMLL1 induction had an impact on self-renewal of this EMP-like population, we determined the serial replating capacity of c-Kit^+^/Cd41^+^ hematopoietic progenitors. The initial increase in CFU observed from the induced c-Kit^+^/Cd41^+^ population was not sustained upon serial replating ([Figure 3](#fig3){ref-type="fig"}F), suggesting the MLL1-dependent increase in CFU occurred during the production of these EMP-like progenitors, rather than within the differentiating population in the CFU assay. Together, these data show that the MLL1-responsive increase in CFU within the c-Kit^+^/Cd41^+^ was not explained by selective survival, proliferation, or increase in self-renewal.

To test the impact of MLL1 induction on hematopoietic development *in vivo*, we induced expression of hMLL1 *in utero* from conception ([Figure S3](#mmc1){ref-type="supplementary-material"}F). At E9.5, the percentage of c-Kit^+^/Cd41^+^ progenitors in the YS was not affected by hMLL1 induction. However, these cells also produced more CFU on a per cell basis ([Figure 3](#fig3){ref-type="fig"}G), similar to the EB observation. We also enumerated hematopoietic cluster cells in the AGM using a whole-mount confocal microscopy technique ([@bib62]). At E10.5, the appearance of c-Kit^+^/Cd31^+^/Runx1^+^ clusters in the ventral wall of the dorsal aorta in the AGM region reflects the emergence of HSCs with definitive potential, whereas c-Kit^neg^/Cd31^+^/Runx1^+^ cells in the same region reflect HE ([@bib23], [@bib45], [@bib61]). In embryos developed with whole-body hMLL1-induction, we observed a significant increase in c-Kit^+^/Cd31^+^ cluster cells within five somites of the vitelline artery ([Figure 3](#fig3){ref-type="fig"}H), suggesting an enhanced EHT process.

Single-Cell Sequencing Demonstrates that MLL1 Influences the Heterogeneity of the c-Kit^+^/Cd41^+^ Population {#sec2.5}
-------------------------------------------------------------------------------------------------------------

Despite being the most enriched for hematopoietic potential, the EB day 6 c-Kit^+^/Cd41^+^ population is likely not homogeneously committed to the hematopoietic lineage. We hypothesized that MLL1 expression may influence cells within this population that respond to hematopoietic conditions of the CFU assay. We therefore analyzed day 6 c-Kit^+^/Cd41^+^ progenitors using single-cell RNA sequencing to determine (1) the heterogeneity of this EMP-like population and (2) whether MLL1 induction changes the composition of this population. Representative pools of sorted c-Kit^+^/Cd41^+^ cells from WT or hMLL1-induced day 6 EBs were subjected to single-cell sequencing ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Unsupervised clustering analysis using both WT and hMLL1-induced progenitors suggested three unique populations within the c-Kit^+^/Cd41^+^ population ([Figures 4](#fig4){ref-type="fig"}A, 4B, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C; the full gene list defining each cluster is shown in [Table S1](#mmc2){ref-type="supplementary-material"}). Cluster 1 (green) was enriched in myeloid and innate immune cell-associated genes such as *Ly6e*, *Ccl3*, *Fcer1g*, *Tyrobp*, and *Cd52* ([Figure S4](#mmc1){ref-type="supplementary-material"}D and [Table S1](#mmc2){ref-type="supplementary-material"}) and enriched the terms "immune system process" and "myeloid leukocyte differentiation" ([Figure S4](#mmc1){ref-type="supplementary-material"}E and [Table S1](#mmc2){ref-type="supplementary-material"}). Cluster 2 (red) was defined by erythroid specific genes such as *Klf1*, *Gata1*, *Hbb-bh1* and enriched the term "erythrocyte differentiation" ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E and [Table S1](#mmc2){ref-type="supplementary-material"}). Interestingly, cluster 3 (blue, "HE-like") retained the expression of many endothelial genes, suggesting recent emergence from HE (e.g. *Esam*, *Cdh5*, *Tie1*, *Kdr*) and enriched the terms "vasculature development" and "regulation of angiogenesis" ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E and [Table S1](#mmc2){ref-type="supplementary-material"}). *In silico* cell-cycle analysis showed a similar distribution and percentage of S/G~2~/M cells within all populations, corroborating our proliferation studies ([Figure S4](#mmc1){ref-type="supplementary-material"}F). This cellular heterogeneity is very similar to that observed in the parallel E9.5 embryo YS c-Kit^+^/Cd41^+^/Cd16/32^+^ population (Kathleen McGrath, Jacquelyn Lillis, and James Palis, personal communication).Figure 4Single-Cell Sequencing Demonstrates that hMLL1 Induction Influences the Heterogeneity of the c-Kit^+^/Cd41^+^ Population(A) Unsupervised hierarchical clustering of gene expression for filtered cells, ordered by average log fold change (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}). The top 15 (clusters 1 and 2) or top 37 (cluster 3) genes enriched in each cluster are shown in a heatmap with gene expression represented on a log scale from red to blue (high to low).(B) T-distributed stochastic neighbor embedding (t-SNE) plot of WT (KH2) and hMLL1-induced c-Kit^+^/Cd41^+^ cells colored by clusters according to (A).(C) Proportion of cells within each cluster is shown in the bar graph.(D) WT or hMLL1-induced cells are arranged by pseudotime axis (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}) with cells colored by clusters according to (A).

To examine the impact of hMLL1 on the distribution of cell types within the c-Kit^+^/Cd41^+^ population, we plotted the percentage of each of the three defined clusters in WT versus hMLL1-induced populations ([Figure 4](#fig4){ref-type="fig"}C). This analysis showed an increase in myeloid and erythroid populations at the expense of the HE-like population ([Figure 4](#fig4){ref-type="fig"}C). We also examined the developmental trajectories of WT and hMLL1-induced samples. Pseudotime analysis with either WT or hMLL1-induced EB progenitors placed the HE-like cluster as a precursor for both erythroid and myeloid/innate immune clusters ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}G). Collectively, these results suggest that hMLL1 induction reshapes the composition of the c-Kit^+^/Cd41^+^ progenitor pool to contain a greater proportion of erythroid- and myeloid-oriented progenitors that may be primed for generating hematopoietic colonies in the CFU assay.

Enhanced Rac/Rho/Integrin Signaling Is a Major Feature of hMLL1-Induced c-Kit^+^/Cd41^+^ Progenitors {#sec2.6}
----------------------------------------------------------------------------------------------------

To understand the mechanisms by which MLL1 induction altered cell fate during hematopoietic progenitor development, we focused on the "HE-like" (cluster 3) cells, since they likely represented the earliest stage of differentiation affected by hMLL1 induction ([Figure 4](#fig4){ref-type="fig"}D). Differentially expressed genes comparing WT versus hMLL1-induced cluster 3 cells were identified and subjected to ingenuity pathway analysis (IPA). This approach showed induction of several canonical signaling pathways in the hMLL1-induced samples, for example "Rac signaling," "integrin signaling," and "RhoGDI signaling" ([Figure S5](#mmc1){ref-type="supplementary-material"}A). To confirm and extend these analyses, we performed bulk RNA sequencing using three independently sorted c-Kit^+^/Cd41^+^ populations from WT or hMLL1-induced EBs. Principal component analysis indicated that the hMLL1-induced samples cluster by genotype ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Again, IPA analysis using differentially expressed genes from the entire c-Kit^+^/Cd41^+^ population recapitulated the results from the single-cell HE-like cluster analysis, showing most significant enrichment of the canonical pathways "Rac signaling," "Rho GTPase signaling," "integrin signaling," and "actin cytoskeleton signaling" ([Figures 5](#fig5){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}C). These signaling annotations share many genes in common ([@bib35]) ([Figure 5](#fig5){ref-type="fig"}B). We confirmed and extended these results using independently sorted samples, including integrins (*Itgb2*, *Itgal*, *Itga4*), Rac/Rho small GTPases (*Rac1*, *Rac2*, *Rhoa*), kinases (*Akt1*, *Pi3kcd*), regulatory subunits or cytoskeleton proteins (*Myl12a/b*, *Actb*, *Arp3*) ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}D). Immunofluorescence staining of F-actin showed increased spontaneous cell spreading in hMLL1-induced Cd41-enriched progenitors when incubated on fibronectin, suggesting enhanced propensity for re-organization of actin filaments upon adhesion ([Figure 5](#fig5){ref-type="fig"}D). Together, these results demonstrate that hMLL1 induction activates a Rac/Rho/integrin cellular signaling state and enhances integrin-mediated adhesion and cytoskeletal rearrangement.Figure 5Genetic Programs and Molecular Pathways Associated with hMLL1 Induction(A) IPA analysis to show the top pathways (by p value) regulated by hMLL1 induction.(B) Venn diagram displays overlap of the top three major signaling pathways by p value affected by hMLL1 induction. Expression heatmap of overlap genes is shown on the right.(C) Quantitative RT-PCR validates the upregulation of Rac/Rho/integrin signaling in hMLL1-induced c-Kit^+^/Cd41^+^ cells. Data show expression relative to *Gapdh* determined by qRT-PCR from three independently sorted samples ± SEM.(D) Representative images showing F-actin visualized with rhodamine-conjugated phalloidin in Cd41^+^ enriched cells ± hMLL1 induction. Arrows indicate spreading actin stress fibers. At least 80 cells in each sample were quantified, and cell areas were measured using ImageJ software. Data represent the average ± SEM from two independent experiments.

hMLL1 Induction Specifically Promotes Integrin-Mediated Cell Adhesion, Increasing Hematopoietic Potential {#sec2.7}
---------------------------------------------------------------------------------------------------------

To test the functional impact of enhanced Rac/Rho/integrin signaling pathways, we first tested cell-surface expression of candidate integrins. Among all MLL1-induced candidates from RNA sequencing analysis, we only observed a significant increase in the percentage of Cd49d+ (encoded by *Itga4*, a subunit of Vla4) cells within the c-Kit^+^/Cd41^+^ day 6 EB cell population ([Figure 6](#fig6){ref-type="fig"}A). Surface expression of the other subunit of Vla4, Cd29 (encoded by *Itgb1*) and other expressed integrins (Cd11a, encoded by *ItgaL*; Cd18, encoded by *Itgb2*) did not change upon hMLL1 induction ([Figure S6](#mmc1){ref-type="supplementary-material"}A). To test whether hMLL1-induced progenitors exhibited an increase in an integrin-mediated function, we allowed cells to adhere to the integrin ligand-coated surfaces and tested baseline adhesion and the effect on hematopoietic potential ([Figure 6](#fig6){ref-type="fig"}B). hMLL1-induced progenitors consistently exhibited increased adhesion to the Vla4 ligands fibronectin and Vcam1 relative to control progenitors ([Figure 6](#fig6){ref-type="fig"}C). This observation was reproduced with additional independent hMLL1-inducible ESC clones ([Figure S6](#mmc1){ref-type="supplementary-material"}B). To investigate the functional outcome of engaging Vla4, we cultured Cd41-enriched progenitors on fibronectin-coated wells for 24 h then transferred all cells to the CFU assay ([Figure 6](#fig6){ref-type="fig"}D). Although fibronectin binding did not influence the CFU of WT cells, it further increased CFUs from hMLL1-induced cells ([Figures 6](#fig6){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}C). To test if this MLL1-dependent CFU increase occurs through Rac-mediated signaling, we treated hMLL1-induced cells briefly with a Rac1 specific inhibitor (NSC23766) and then performed CFU assays. While WT cells did not exhibit changes in CFU frequency, use of the Rac inhibitor on hMLL1-induced cells significantly decreased CFU frequencies, bringing them back to levels observed in WT untreated cells ([Figures 6](#fig6){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}D). These data collectively suggest that the enhanced signaling state produced by hMLL1 induction is Rac1-dependent and increases responsiveness to Vla4 ligands, resulting in enhanced hematopoietic commitment from the transitional c-Kit^+^/Cd41^+^ population.Figure 6hMLL1 Induction Specifically Promotes Integrin-Mediated Cell Adhesion and Further Expands CFU(A) Flow cytometry to detect Cd49d expression in c-Kit^+^/Cd41^+^ gated EB cells. Quantification of one representative experiment from three independent differentiation experiments is shown on the right. Data show the average ± SEM, n = triplicate cultures.(B) Experimental procedure to test integrin function. Day 6 EB Cd41^+^ enriched WT or hMLL1-inducible cells were cultured on integrin ligand (fibronectin or Vcam1)-coated plates for the indicated time and tested for adhesion or CFU content.(C) Cell adhesion of Cd41^+^ enriched progenitors to fibronectin and Vcam1. Data are representative of four independent experiments and presented as the average of triplicate cultures ± SEM.(D) CFU assay using sorted Cd41^+^ EB progenitors following 24 h adhesion. Adherent cells were harvested with dissociation buffer and pooled with remaining suspension cells, then counted for CFU assay. Left: both hMLL1-inducible and WT cells were adhered to fibronectin fragment and then followed by CFU assay. One representative experiment of three is shown as the average ± SEM, n = 3 triplicate cultures. Right: quantification of CFU fold changes with Dox, fibronectin fragment, or Rac1 inhibitor (NSC23766, 10 μM). The graph show data pooled from 3 to 4 independent experiments (n = 3 for WT; n = 4 for hMLL1i, with each data point representing the average of triplicate cultures) representing the overall average ± SEM.

Discussion {#sec3}
==========

Here, we present a model system in which increasing MLL1 protein levels within a physiologically reasonable range can be achieved and show that this perturbation selectively increases hematopoietic potential during a transition from endothelial to hematopoietic fate. The approach used here has been very useful for testing the effect of consistent and physiologic overexpression of several transcription factors including Scl, Cdx4, Hoxb4, Mix1, and Notch1 ([@bib22], [@bib31], [@bib32], [@bib40], [@bib42], [@bib57], [@bib58]). In contrast to the effect of hMLL1 induction, Cdx4 or Hoxb4 overexpression increases c-Kit^+^/Cd41^+^ hematopoietic progenitors at an earlier stage, promoting formation of HE and subsequently, hematopoietic potential ([@bib55], [@bib57]). While inducing hMLL1 apparently does not numerically affect HE or increase c-Kit^+^/Cd41^+^ progenitors, it reshapes the composition of this population, resulting in enhanced hematopoietic potential. Interestingly, we also observe an increase in hematopoietic clusters from HE in the dorsa aorta of hMLL1-induced E10.5 embryos, suggesting that hMLL1 plays a parallel role in a distinct hemogenic endothelial site *in vivo*. The specific impact of MLL1 induction may be due to the regulation of a yet undefined network regulating Rac1 activity, integrin-mediated adhesion, and cytoskeletal rearrangement during the EHT process.

The application of single-cell RNA sequencing in this setting enabled us to investigate the heterogeneity of a murine EB-derived EMP-like hematopoietic progenitor pool, which has not yet been addressed. Comparative analysis of our *in vitro* day 6 c-Kit^+^/Cd41^+^ EMP-like progenitor with the E9.5 *in vivo* YS EMP ([@bib39]) single-cell sequencing data showed a very similar composition, including a residual HE-like population, an erythroid and a myeloid/innate immune population (Kathleen McGrath, Jacquelyn Lillis, and James Palis, personal communication). The similarities in transcriptome-defined populations *in vivo* and *in vitro* underscore the relevance of the ESC system for dissecting sequential developmental stages of hematopoiesis. The presence of a residual HE-like gene expression signature is consistent with the observation that the onset of hematopoietic potential commences with Cd41 expression within a hemogenic endothelial population ([@bib34], [@bib39]), thus the c-Kit^+^/Cd41^+^ population likely represents an asynchronous pool of cells with varying degrees of "memory" of hemogenic endothelial identity. We interpret the single-cell transcriptome data to suggest that hMLL1 induction alters the composition of the EMP-like progenitor pool, resulting in either more efficient commitment to the hematopoietic lineages at the expense of the HE-like population, or that hMLL1 induction accelerated kinetics of departure from an HE-like state toward the myeloid- and erythroid-primed progenitors. Given our observations that hMLL1 induction does not increase the c-Kit^+^/Cd41^+^ population, as well as the similarity of the kinetics developing hemogenic populations, it seems more likely that hMLL1 induction promotes hematopoiesis by driving more efficient commitment to multilineage hematopoietic fates.

A very surprising finding was the fact that hMLL1 induction did not affect *Hox* cluster gene expression. The generally low expression levels of *Hoxa-d* clusters in EB-derived hematopoietic progenitors has been noted by others ([@bib12], [@bib44]). This feature of EB-derived and YS-derived progenitors may underlie their inability to generate definitive HSCs since the parallel or immunophenotypically similar fetal liver progenitors can express much higher *Hox* levels ([@bib12]). We speculate that the acquisition of a *Hoxa* signature may need additional sequence-specific transcriptional inputs (e.g., retinoic acid signaling) ([@bib12]), while MLL1 itself is not capable of such induction, consistent with the role of Trithorax as a maintenance factor rather than inducer of gene expression ([@bib50]). In fact, preliminary data suggest that *Hoxa* induction by retinoic acid receptor agonists is sustained more efficiently in the presence of induced hMLL1 (W.Y., unpublished data).

Interestingly, induction of hMLL1 does not lead to leukemic transformation as with MLL fusion oncoproteins in other cellular settings. Recent work by Bueno et al. demonstrates that ectopic expression of MLL-AF4 is not sufficient to induce leukemic transformation in human ESC-derived hematopoietic cells ([@bib7], [@bib6]), consistent with our observation that inducing MLL-ENL does not transform ES-derived hematopoietic progenitors (W.Y. and D.B., unpublished data). These findings raise questions about the responsiveness of EMP-like populations to transformation, specifically by oncogenes that may require induction of a *Hox* program. The lack of or limited *Hox* induction in hMLL1-induced cultures or the distinct dynamic pattern ([@bib53], [@bib63]) in MLL fusion transduced EBs may represent a hurdle that restrains cell growth or transformation. Overcoming this hurdle may require developmental context and *Hox* regulators in addition to MLL1. Defining exact window of development and mechanisms of *Hox* locus responsiveness may shed light on the cell of origin and pediatric association of *MLL1* translocations ([@bib1]).

In this study, we identified Rac/Rho/integrin signaling as a major axis activated by hMLL1 induction within the EMP-like population of developing EBs. hMLL1 induction resulted in increased *Itga4*, *Itgal*, and *Itgb2* transcripts and increased Cd49d surface expression. hMLL1 induction also promotes integrin-mediated cell adhesion and further activation of integrin signaling through Vla4, resulting in enhanced CFU from this EMP-like population. Several previous studies have implicated the Rac/Rho/integrin axis as limiting for hematopoietic development and homeostasis. First, the Cd49d^+^ fraction of ESC-derived endothelium is enriched in both primitive and definitive hematopoietic progenitor activity ([@bib52]). Second, Rac1 activation during early embryonic hematopoiesis in the dorsal aorta, as well as Rac2 and Cdc42 activation in Lin^neg^/c-Kit^+^/Sca-1^+^ HSPCs, is associated with Vla4-mediated adhesion, migration, engraftment, and survival of HSPCs ([@bib20], [@bib59]). Interestingly, studies identifying Runx1 target genes in hemogenic endothelia of the embryo or in EBs also revealed integrin signaling, Rho signaling, cytoskeletal organization, and cell adhesion as enriched pathways regulated by Runx1 ([@bib19], [@bib35]). The effect of Runx1 induction has been proposed to be in part through direct regulation of the integrin Cd61 (*Itgb3*) ([@bib35]). The cause of widespread Rac/Rho activation in hMLL1-induced EMP-like progenitors is unclear but may reflect a complex combination of direct and indirect effects of increasing MLL1 levels. Since we observe downregulation of several RhoGEFs, it is also possible that compensatory upregulation of the Rac/Rho pathways results in the more active adhesion phenotype in MLL1-induced progenitors and could account for the greater number of hematopoietic cells in the aortic clusters. Collectively, our data underscore the impact of integrin/Rac/Rho signaling in the EHT process, and that Runx1 and MLL1 may both regulate this critical step in parallel.

In summary, utilizing this physiologic MLL1-inducible model system revealed an unanticipated connection between MLL1 and integrin-mediated signaling that appears to enhance the efficiency of EHT. Whether these pathways are conserved in the later waves of hematopoiesis in the embryo and adult, and whether they can collaborate with other signals for more efficient production of HSPCs, will be important future questions.

Experimental Procedures {#sec4}
=======================

ESC Culture and Differentiation {#sec4.1}
-------------------------------

ESCs were maintained on embryonic fibroblasts using standard conditions ([@bib17]). For *in vitro* differentiation, single-cell suspensions from dissociated ESC cultures were seeded at 10,000--20,000 cells/mL in Petri dishes (Fisher) with orbital rotation (50 rpm, Labnet Orbit 1000). The differentiation medium was Iscove\'s modified Dulbecco\'s medium (Mediatech) containing 15% fetal bovine serum (Gibco), 2 mM L-glutamine (Mediatech), 1% penicillin/streptomycin (Mediatech), 200 μg/mL holo bovine transferrin (Millipore), 4.5 × 10^−4^ M monothioglycerol (Sigma) and 50 μg/mL ascorbic acid (Sigma). Doxycycline (Enzo Life Sciences) was added to the differentiation medium at 1--2 μg/mL for the times indicated in each figure legend.

Flow Cytometry, Cell Isolation, and Sorting {#sec4.2}
-------------------------------------------

EBs were dissociated with collagenase (0.8 U/mL, Sigma) and dispase I (2 mg/mL, Sigma) and then incubated with the indicated antibodies (Biolegend or eBiosciences). Stained cells were analyzed or sorted using an LSR Fortessa or FACSAria Fusion, respectively (BD Biosciences). Gating was based on either single color or isotype control staining. Enrichment was performed using Miltenyi Cd41 magnetic beads. Flow cytometry data were analyzed using FlowJo software (TreeStar).

Single-Cell Sequencing, RNA Sequencing, and Bioinformatics {#sec4.3}
----------------------------------------------------------

Single-cell RNA sequencing was performed with singlet-gated, DAPI-negative, c-Kit^+^/Cd41^+^ cells from day 6 EBs sorted using a FACSAria Fusion. Cell purity was determined by post-sort re-analysis and was typically \>90% ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Approximately 4,000 sorted cells were used to generate libraries and sequenced by the University of Colorado Cancer Center Genomics and Microarray core facility. Bulk RNA sequencing was performed using sorted c-Kit^+^/Cd41^+^ pools of cells from WT (KH2) or hMLL1-inducible EBs incubated with doxycycline from day 4 to day 6. Three separate differentiation experiments were performed with WT (KH2) and hMLL1i differentiated in parallel. Detailed sequencing data analysis and methods can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analyses {#sec4.4}
--------------------

Significance was analyzed in all studies using unpaired Student\'s t tests and standard error of the mean (SEM) with ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 considered significant unless otherwise indicated in the figure legends. GraphPad Prism or Microsoft Excel software was used to perform the statistical calculations.
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